# US 2005/0233301 A1 · Cryopreservation of haptenized tumor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233301 A1
- Document ID: US20050233301A1
- Status: Published application
- Kind: A1
- Application number: 11/009,192
- Filed: 2004-12-09
- Published: 2005-10-20
- Earliest claimed: 2002-06-10
- Inventors: David Berd; Lorne Erdile; Margalit Mokyr
- Web page: https://patentgrep.com/patent/US20050233301A1

## CPC

- A01N 1/125: Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
- A01N 1/10: Preservation of living parts
- A61P 35/00: Antineoplastic agents
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells during storage. The haptenized tumor cells also retain cell-associated antigens and haptens, and are as immunogenic, i.e., capable of inducing immunotherapeutic response, as fresh vaccine in a mouse model of metastatic disease. In a specific embodiment, haptenized cells are exposed to a solution of 8% sucrose, 10% human serum albumin in Hank's buffered solution, and then frozen to −80° C. overnight and then stored in a liquid nitrogen freezer. Methods of storing haptenized tumor cells and compositions are also provided.

## Claims

### Claim 1

A method of preserving haptenized tumor cells, which method comprises:
(i) contacting the haptenized tumor cells with a freezing medium, wherein the freezing medium comprises sucrose, human serum albumin and an isotonic buffered solution; and
(ii) freezing the tumor cells,
whereby the immunogenicity of the tumor cells is preserved.

### Claim 2 (depends on 1)

The method of claim 1, wherein the isotonic buffered saline solution is Hank's buffered solution.

### Claim 3 (depends on 1)

The method of claim 1, wherein the freezing medium comprises 8% sucrose, 10% human serum albumin and the isotonic buffered saline solution is Hank's buffered solution.

### Claim 4 (depends on 1)

The method of claim 1, wherein the temperature is from about −80° C. to about −196° C.

### Claim 5 (depends on 1)

The method of claim 1, wherein at least 70% of the level of at least one tumor cell-associated antigen (TCAA) is preserved after about 3 months storage at a temperature of at least −80° C.

### Claim 6 (depends on 5)

The method of claim 5, wherein at least 90% of the TCAA is preserved.

### Claim 7 (depends on 1)

The method of claim 1, wherein at least 50% of the haptenized tumor cells are preserved intact after about 3 months storage at a temperature of at least −80° C.

### Claim 8 (depends on 7)

The method of claim 7, wherein at least 70% of the haptenized tumor cells are preserved intact.

### Claim 9 (depends on 1)

The method of claim 1, wherein the tumor cells are selected from the group consisting melanoma cells, ovarian cancer cells, colorectal cancer cells, small cell lung cancer cells, kidney cancer cells, breast cancer cells, and leukemia cells.

### Claim 10 (depends on 9)

The method of claim 9, wherein the tumor cells are melanoma cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein the tumor cells are haptenized with at least one hapten selected from the group consisting of DNP, TNP, and sulfanilic acid.

### Claim 12 (depends on 9)

The method of claim 9, wherein the tumor cells are haptenized with DNP.

### Claim 13 (depends on 11)

The method of claim 11, wherein the tumor cells are haptenized with at least two different haptens.

### Claim 14

A method of storage for haptenized tumor cells for use in a vaccine, which method comprises storing a haptenized tumor cells and a freezing medium composition at a temperature below the freezing temperature for at least 3 months.

### Claim 15 (depends on 14)

The method of claim 14, wherein the temperature is from about −80° C. to −196° C.

### Claim 16 (depends on 12)

The method of claim 12, wherein the tumor cells are haptenized with at least one hapten selected from DNA and sulfanilic acid.

### Claim 17

A composition comprising haptenized tumor cells for use in a vaccine and a freezing medium, wherein the freezing medium comprises sucrose, human serum albumin and an isotonic buffered saline solution.

### Claim 18 (depends on 15)

The composition of claim 15, wherein the freezing medium comprises 8% sucrose, 10% human serum albumin and the isotonic buffered saline solution is Hank's buffered solution.

### Claim 19 (depends on 15)

The composition of claim 15, wherein the tumor cells are selected from the group consisting melanoma cells, ovarian cancer cells, colorectal cancer cells, small cell lung cancer cells, kidney cancer cells, breast cancer cells, and leukemia cells.

### Claim 20 (depends on 17)

The composition of claim 17, wherein the tumor cells are melanoma cells.

### Claim 21 (depends on 15)

The composition of claim 15, wherein the tumor cells are haptenized with at least one hapten selected from the group consisting of DNP, TNP, and sulfanilic acid.
